• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER Back to Search Results
Catalog Number 1BBWGQ506A2
Device Problems Restricted Flow rate (1248); High Test Results (2457); Filtration Problem (2941)
Patient Problem No Patient Involvement (2645)
Event Date 04/04/2020
Event Type  malfunction  
Manufacturer Narrative
Investigation is in process.A follow-up report will be provided.
 
Event Description
The customer reported elevated white blood cell (wbc) content in a filtered whole blood unit.There was not a transfusion recipient or patient involved at the time of whole blood processing, therefore no patient information is reasonably known at the time of the event.Donor unit #: (b)(6).
 
Manufacturer Narrative
This report is being filed to provide additional information in h.3, h.6 and h.10.Investigation: one filter from the collection set was returned for evaluation.The leukoreduction filter was tested for flow rate and air leaks.A slow flow rate of 42 ml/min was noted, and it was confirmed there were no air leaks.The filters were dyed with toludine blue.We noticed that the first, third, and fourth filter membranes from the inflow side of the filter were locally dyed dark with toluidine blue.The filter was disassembled to observe the appearance of filter membranes and noticed creases in the filter membranes of the filter.The creases in the filter were not different from those in conforming products and in the filter membranes and aggregation was not observed in the any filter membranes.The manufacturing records, test records, and inspection records were reviewed for abnormalities and none were found.The records regarding the particulate removal rates of the filter membranes were reviewed.All membranes conformed to established specification.Shipping testing was performed on the reserve samples from the reported lot number.The reserve samples were also visually examined, and the solution volume and solution composition were tested with no abnormalities noted.All product conformed to the established specification.Root cause: we control to maintain cationization levels above a certain level during the production of filter membranes in order to prevent from leukocyte leakage.Where a cationization level is high, filtration rate is likely to be low.The above-mentioned investigation results revealed that there were no abnormalities in the manufacturing record and the testing and inspection record of the reported lot number.The returned filters also revealed no abnormalities in themselves.We noticed that the third and fourth filter membranes were locally dyed dark with toluidine blue.Therefore, occlusion may have occurred and blood may have been filtered by the filter area which was smaller than usual and the linear speed (flow rate per unit area) increased, and then leukocyte leakage occurred.In addition, we confirmed some areas of the filter membranes that had not been used for filtration concerning both filters.It was likely to take a longer time for priming of the filter for some reason; however, we were not able to identify the cause of the issue.We infer that the unused areas of the filter membranes impeded blood flow and it caused to increase the linear speed of the areas where blood flowed.As a result, leukocyte leakage may have occurred.The instructions for use provide a caution to not squeeze or apply pressure to the filter while it is attached to the bag containing the filtered blood and also to clamp the blood-filled tubing before blood enters the filter in order to avoid leukocyte leakage.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMUFLEX BLOOD BAG SYSTEM
Type of Device
IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER
Manufacturer (Section D)
TERUMO CORPORATION
fujinomiya
MDR Report Key10062439
MDR Text Key193049919
Report Number9681839-2020-00056
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial,Followup
Report Date 05/15/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2022
Device Catalogue Number1BBWGQ506A2
Device Lot Number190820AG
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer04/10/2020
Was the Report Sent to FDA? Yes
Initial Date Manufacturer Received 04/22/2020
Initial Date FDA Received05/15/2020
Supplement Dates Manufacturer Received05/18/2020
Supplement Dates FDA Received06/03/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-